GET DAILY SIGNALSWhy Is Alphatec Holdings (ATEC) Stock Down -32.63% Today?
Key Takeaways
- ATEC shares plunged about 32.63% in Friday's session after third-quarter results and full-year guidance fell short of Wall Street expectations.
- The primary catalyst was a revenue miss driven by weaker-than-expected biologics attachment, which also forced the company to cut its fiscal 2026 outlook.
- A BMO Capital downgrade to Market Perform from Outperform, with a price-target cut to $8 from $12, compounded the selling pressure.
- Despite the shortfall, surgical hardware revenue grew 17% and case volumes rose roughly 20%, signaling resilient underlying demand for the company's spine procedures.
- Traders are now watching whether the company can stabilize biologics performance and whether further analyst estimate revisions follow.
- For more detail on Price Targets, Earnings, and Forecast data, explore the additional pages available for this ticker.
- You can also explore Trending AI Robots to see AI-driven trading strategies that may be positioned around this and other symbols.
Opening Summary
Alphatec Holdings, Inc. (ATEC), a medical device company focused on spine surgery through its Alphatec Spine, EOS imaging, and SafeOp Surgical businesses, saw its stock tumble sharply in Friday's trading. After closing the prior session at $11.37, the shares were trading around $7.66 intraday, a decline of roughly 32.63%. The selloff followed the company's third-quarter earnings release, which missed consensus estimates and included a reduction to full-year revenue guidance, prompting at least one analyst downgrade.
Third-Quarter Revenue Miss and Guidance Cut
The dominant driver of the decline was Alphatec's third-quarter report. The company posted revenue of approximately $221.2 million, up 13% year over year but below the consensus estimate of around $225 million. Management attributed the shortfall primarily to lower biologics attachment, which reduced revenue-per-case and offset otherwise healthy procedure growth. The company said its GAAP net loss narrowed to about $5.5 million from $28.6 million a year earlier, but the top-line miss overshadowed that improvement.
More concerning for investors was the guidance revision. Alphatec cut its full-year 2026 revenue outlook to approximately $862 million, a reduction of roughly $20 million, as the biologics softness persisted through the fourth quarter. The company reiterated that improving biologics performance is a clear priority, but the combination of a revenue miss and a lowered forecast triggered an aggressive repricing of the shares.
Analyst Downgrade Weighs on Sentiment
The earnings-driven selloff was amplified by a downgrade from BMO Capital, which lowered ATEC to Market Perform from Outperform and cut its price target to $8 from $12. The analyst cited the flat biologics attachment, the $20 million guidance reduction, and a 5% decline in revenue per case, noting that the firm now models the company's 2027 revenue, EBITDA, and free cash flow below its long-range plan. While the broader analyst consensus remains at Buy with a significantly higher average target, the prominent downgrade reinforced the bearish narrative in the immediate term.
Market Context and Trading Activity
The magnitude of the move was driven by heavy volume, as the earnings release and analyst action prompted a sharp repricing well above typical daily activity. The decline also coincided with broader pressure on growth-oriented and technology-adjacent names, where cautious corporate guidance weighed on sentiment. However, ATEC's drop was primarily company-specific, reflecting disappointment in the biologics segment rather than a broad healthcare-sector selloff. The shares broke decisively below prior support levels, with the stock trading near multi-year lows as momentum turned sharply negative.
What Comes Next for ATEC
Looking ahead, investors will focus on whether Alphatec can demonstrate a turnaround in biologics attachment and revenue-per-case trends in the coming quarters. The company continues to point to strong underlying fundamentals, including 17% hardware growth, approximately 20% case-volume growth, and a 25% increase in new surgeon adoption, suggesting demand for its procedural solutions remains robust. Key uncertainties include the pace of biologics recovery, potential further estimate revisions from analysts, and the company's progress toward its long-range financial targets. With the stock now trading well below recent levels, the near-term path will likely hinge on execution in the biologics business and management's commentary on subsequent earnings calls.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers in the present environment are featured in this section. Explore the page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ATEC in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 22, 2026
ATEC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 45 similar instances where the stock broke above the upper band. In 38 of the 45 cases the stock fell afterwards. This puts the odds of success at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 57 cases where ATEC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ATEC as a result. In 75 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ATEC just turned positive on October 22, 2026. Looking at past instances where ATEC's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +8.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 266 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 194 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ATEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-145.506) is very low in comparison to the industry average of (3.870). P/E Ratio (-16.014) is within average values for comparable stocks, (1.382). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices
Advertisement